Breaking News Instant updates and real-time market news.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

, NVS

Novartis

$80.08

0.22 (0.28%)

16:33
05/18/17
05/18
16:33
05/18/17
16:33

Diplomat Pharmacy now dispensing Novartis' Rydapt for acute myeolid leukemia

Diplomat Pharmacy (DPLO) is now dispensing Rydapt, recently approved by the FDA. Rydapt is manufactured by Novartis (NVS) and is approved to treat newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The FDA also approved Rydapt to treat aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell leukemia.

DPLO

Diplomat Pharmacy

$17.44

-0.17 (-0.97%)

NVS

Novartis

$80.08

0.22 (0.28%)

  • 19

    May

  • 06

    Jun

  • 26

    Jun

DPLO Diplomat Pharmacy
$17.44

-0.17 (-0.97%)

03/01/17
BARD
03/01/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy results should satisfy lowered expectations, says Baird
Baird analyst Eric Coldwell noted Diplomat Pharmacy reported Q4 results that were in-line with expectations and provided guidance that is likely ahead of lowered expectations. Coldwell maintained his Outperform rating and $20 price target on Diplomat shares.
03/06/17
BARD
03/06/17
NO CHANGE
Target $20
BARD
Outperform
Significant opportunities ahead for Diplomat Pharmacy, says Baird
Baird analyst Eric Coldwell traveled with Diplomat Pharmacy and now believes there are significant opportunities ahead as its platform remains differentiated and last year reset expectations. Coldwell said crisper execution is required, but he sees a pathway to returning growth in 2018 and beyond. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
05/09/17
LEHM
05/09/17
NO CHANGE
Target $20
LEHM
Overweight
Diplomat Pharmacy price target raised to $20 from $17 at Barclays
Barclays analyst Eric Percher raised his price target for Diplomat Pharmacy to $20 citing the "solid" Q1 results and acquisition of WRB Communications. The analyst maintains an Overweight rating on the shares.
05/09/17
BARD
05/09/17
NO CHANGE
Target $20
BARD
Outperform
Diplomat Pharmacy shares should react positively to 'clean' quarter, says Baird
Baird analyst Eric Coldwell said Diplomat Pharmacy reported its "cleanest and calmest" quarter in a long time and as a result he believes the shares should react positively. He noted the earnings beat, unchanged guidance, and management's enthusiastic comments about upcoming catalysts, including upcoming FDA approvals. Coldwell reiterated his Outperform rating and $20 price target on Diplomat Pharmacy shares.
NVS Novartis
$80.08

0.22 (0.28%)

04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.
04/21/17
ROTH
04/21/17
NO CHANGE
Target $12
ROTH
Buy
Conatus price target raised to $12 from $4 at Roth Capital
Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.
05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.

TODAY'S FREE FLY STORIES

CYH

Community Health

$8.46

-0.25 (-2.87%)

16:38
07/26/17
07/26
16:38
07/26/17
16:38
Earnings
Community Health sees Q2 EPS ex-items (25c), consensus 6c »

Sees Q2 revenue $4.144B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 23

    Aug

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:38
07/26/17
07/26
16:38
07/26/17
16:38
Earnings
Whirlpool lowers FY17 ongoing EPS view to $14.50-$15.00 from $14.75-$15.50 »

For FY17, the company now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIGI

Selective Insurance

$50.60

-0.7 (-1.36%)

16:38
07/26/17
07/26
16:38
07/26/17
16:38
Hot Stocks
Selective Insurance revises FY17 guidance »

After two quarters of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CSGP

CoStar Group

$281.32

-0.65 (-0.23%)

16:37
07/26/17
07/26
16:37
07/26/17
16:37
Earnings
CoStar Group sees Q3 EPS $1.09-$1.15, consensus $1.20 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

WPG

Washington Prime

$9.11

-0.02 (-0.22%)

16:37
07/26/17
07/26
16:37
07/26/17
16:37
Earnings
Washington Prime sees Q3 20c-23c, one estimate 23c »

Sees Q3 adjusted FFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

LVS

Las Vegas Sands

$61.65

-0.97 (-1.55%)

16:37
07/26/17
07/26
16:37
07/26/17
16:37
Hot Stocks
Las Vegas Sands reports Q2 Venetian Macao revenue $687M »

The Venetian Macao…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CSGP

CoStar Group

$281.32

-0.65 (-0.23%)

16:37
07/26/17
07/26
16:37
07/26/17
16:37
Earnings
CoStar Group raises 2017 EPS outlook to $4.42-$4.52, consensus $4.37 »

Raises 2017 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

SIGI

Selective Insurance

$50.60

-0.7 (-1.36%)

16:36
07/26/17
07/26
16:36
07/26/17
16:36
Earnings
Selective Insurance reports Q2 EPS 70c, consensus 73c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WPG

Washington Prime

$9.11

-0.02 (-0.22%)

16:36
07/26/17
07/26
16:36
07/26/17
16:36
Earnings
Washington Prime reports Q2 EPS 72c vs. 10c a year ago »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

CSGP

CoStar Group

$281.32

-0.65 (-0.23%)

16:36
07/26/17
07/26
16:36
07/26/17
16:36
Earnings
CoStar Group reports Q2 EPS 86c, consensus 63c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

TBK

Triumph Bancorp

$28.80

0.2 (0.70%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Conference/Events
Triumph Bancorp to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 18

    Sep

ORLY

O'Reilly Automotive

$187.43

0.58 (0.31%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
O'Reilly Automotive reports Q2 EPS $3.10, consensus $2.89 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
On Assignment sees Q3 adjusted EPS 73c-76c, consensus 80c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CNO

CNO Financial

$21.75

-0.52 (-2.34%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Earnings
CNO Financial reports Q2 EPS 48c, consensus 37c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BWLD

Buffalo Wild Wings

$122.65

-1.05 (-0.85%)

16:35
07/26/17
07/26
16:35
07/26/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Buffalo Wild Wings »

Buffalo Wild Wings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

  • 11

    Sep

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Hot Stocks
Whirlpool increases share repurchase authorization to $2.35B »

"Our strong free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:34
07/26/17
07/26
16:34
07/26/17
16:34
Earnings
Breaking Earnings news story on Duke Realty »

Duke Realty sees 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

BXS

BancorpSouth

$30.25

-1 (-3.20%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
BancorpSouth raises quarterly dividend 12% to 14c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 18

    Sep

DRE

Duke Realty

$28.42

0.69 (2.49%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Duke Realty reports Q2 core FFO 32c, consensus 31c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

ASGN

On Assignment

$51.71

-1.57 (-2.95%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
On Assignment reports Q2 EPS 62c, consensus 72c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ANIK

Anika Therapeutics

$47.99

-0.27 (-0.56%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Anika Therapeutics reports Q2 EPS 76c, consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

UVSP

Univest

$30.00

-0.3 (-0.99%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Breaking Earnings news story on Univest »

Univest reports Q2 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 01

    Aug

O

Realty Income

$57.92

0.49 (0.85%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Hot Stocks
Realty Income sees FY17 EPS $1.15-$1.20, consensus $1.22 »

Company estimates FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WHR

Whirlpool

$190.19

-0.76 (-0.40%)

16:33
07/26/17
07/26
16:33
07/26/17
16:33
Earnings
Whirlpool reports Q2 EPS $3.35, consensus $3.54 »

Reports Q2 revenue $5.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMO

Capstead Mortgage

$9.99

-0.06 (-0.60%)

16:32
07/26/17
07/26
16:32
07/26/17
16:32
Earnings
Capstead Mortgage reports Q2 EPS 14c, consensus 20c »

Book value per common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.